Literature DB >> 15023169

Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.

T Yamamoto1, S Umegae, T Kitagawa, K Matsumoto.   

Abstract

AIM: To examine whether mucosal cytokine production during remission after resection for Crohn's disease is a predictor of future relapse.
METHODS: Thirty-six patients who remained in remission after resection for terminal ileal or ileo-caecal Crohn's disease were included. At enrollment, blood and mucosal (ileal and rectal biopsies) samples were collected. All patients were followed up regularly for 1 year after enrollment and the disease activity was assessed according to the Crohn's disease activity index.
RESULTS: Twenty patients remained in remission and 16 patients relapsed during the 1-year follow-up. Interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha levels in the ileal mucosa were significantly higher in relapsed patients than in patients in remission. These cytokine levels in the rectal mucosa were not associated with relapse. Conventional blood markers and plasma cytokine levels did not correlate with relapse. Amongst the clinical parameters, a younger age, short disease duration before operation and fistulating disease were risk factors for relapse. In multivariate analysis, only the ileal interleukin-6 level was an independent significant predictor for relapse.
CONCLUSIONS: The interleukin-6 level in the ileal mucosa during remission after resection for ileal or ileo-caecal Crohn's disease is an independent significant predictor for future relapse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023169     DOI: 10.1111/j.1365-2036.2004.01899.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis.

Authors:  Y Nishio; T Ando; O Maeda; K Ishiguro; O Watanabe; N Ohmiya; Y Niwa; K Kusugami; H Goto
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 2.  Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field.

Authors:  Anna M Borowiec; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

Review 3.  Predictors of recurrence of Crohn's disease after ileocolectomy: a review.

Authors:  Tara M Connelly; Evangelos Messaris
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Daniela Basso; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Nicolò Bassi; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

5.  NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer.

Authors:  Aurélie Couturier-Maillard; Thomas Secher; Ateequr Rehman; Sylvain Normand; Adèle De Arcangelis; Robert Haesler; Ludovic Huot; Teddy Grandjean; Aude Bressenot; Anne Delanoye-Crespin; Olivier Gaillot; Stefan Schreiber; Yves Lemoine; Bernhard Ryffel; David Hot; Gabriel Nùñez; Grace Chen; Philip Rosenstiel; Mathias Chamaillard
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

6.  LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease.

Authors:  Mark M T J Broekman; Hennie M J Roelofs; Frank Hoentjen; Renske Wiegertjes; Nicole Stoel; Leo A Joosten; Dirk J de Jong; Geert J A Wanten
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 7.  The Role of Inflammation in Crohn's Disease Recurrence after Surgical Treatment.

Authors:  B Sensi; L Siragusa; C Efrati; L Petagna; M Franceschilli; V Bellato; A Antonelli; C Arcudi; M Campanelli; S Ingallinella; A M Guida; A Divizia
Journal:  J Immunol Res       Date:  2020-12-26       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.